Clinical Trials Logo

Clinical Trial Summary

Study Question: In infants who are born at gestational ages of 23 0/7 to 27 6/7 weeks, does lowering the concentration of supplemental oxygen to target an arterial oxygen saturation by pulse oximetry (SpO2)of 85-89% compared with 91-95%, from the day of birth until the baby's first discharge home, increase the probability of survival without severe neurosensory disability to a corrected age of 18 months?


Clinical Trial Description

Most extremely preterm babies require supplemental oxygen for several weeks or even months after birth. The goal of oxygen therapy is to achieve adequate oxygen delivery to the tissues without causing oxygen toxicity and oxidative stress. At present, this goal is elusive in very immature infants. Although it is standard practice in modern neonatal intensive care units to monitor arterial oxygen saturations via pulse oximetry, there is insufficient evidence to guide the choice of the upper and lower alarm limits. A rigorous trial with long-term follow up is urgently needed and long overdue to determine whether oxygen exposure can be reduced safely in extremely preterm infants without increasing the risk of hypoxic death or disability. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00637169
Study type Interventional
Source McMaster University
Contact
Status Completed
Phase Phase 3
Start date December 2006
Completion date December 2012

See also
  Status Clinical Trial Phase
Terminated NCT00636324 - Level of Continuous Positive Airway Pressure (CPAP) in Preterm Infants After Extubation (L-CPAP Study) Phase 2
Completed NCT00433212 - Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV) Phase 3